Related Experiment Videos
[Red cell substitutes: perfluorocarbon emulsions and hemoglobin solutions]
B Rémy1, G Deby-Dupont, V D'Ans
1Département d'anesthésie-réanimation, centre hospitalier universitaire du Sart Tilman, Liège, Belgique.
Annales Francaises D'Anesthesie Et De Reanimation
|April 20, 1999
Summary
Perfluorocarbon (PFC) emulsions and hemoglobin (Hb) solutions are reviewed as oxygen carriers. While PFCs support tissue oxygenation, modified Hb solutions are progressing through clinical trials for blood substitute applications.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Critical Care Medicine
Context:
- Perfluorocarbon (PFC) emulsions and hemoglobin (Hb) solutions represent advanced oxygen-carrying technologies.
- These artificial oxygen carriers are being developed to address limitations in traditional blood transfusions and oxygen delivery.
- Current research focuses on their efficacy and safety in various clinical settings.
Purpose:
- To review and synthesize current data on perfluorocarbon (PFC) emulsions and hemoglobin (Hb) solutions.
- To analyze the properties, applications, and clinical trial status of these oxygen therapeutics.
- To provide an overview of their potential as blood substitutes and tissue oxygenation support.
Summary:
- PFCs are synthetic oxygen carriers administered as emulsions, supporting tissue oxygenation during hemodilution and are exhaled unchanged.
- Modified Hb solutions, including diaspirin cross-linked hemoglobin (DCLHb), are undergoing Phase III trials for surgical and trauma applications.
- Both PFCs and Hb solutions aim to enhance oxygen delivery, with Hb solutions showing promise as potential blood substitutes.
Impact:
- These oxygen carriers offer potential alternatives to blood transfusions, particularly in situations of extreme blood loss or limited blood availability.
- Successful clinical application could revolutionize emergency medicine, surgery, and critical care by improving tissue oxygenation.
- Further research and clinical trials are crucial to establish the full therapeutic potential and safety profile of PFCs and Hb solutions.